RMC-6236 / DARAXON portfolio
Daraxonrasib API
RMC-6236 active pharmaceutical ingredient for development and registration programs. U.S. FDA DMF 43871.
Product overview
Active pharmaceutical ingredient
Daraxon supplies daraxonrasib API, also known as RMC-6236, alongside two downstream SDD material formats. Discuss API specifications, quantities and the documentation required by your development program with our technical team.
PubChem · Daraxonrasib↗- Product
- Daraxonrasib API
- Development code
- RMC-6236
- Material format
- Active pharmaceutical ingredient
- Research context
- RAS(ON) multi-selective inhibitor
- U.S. FDA DMF
- 43871 · Type II
- Submission date
- 2026-03-17
- Status in the 2026 Q3 list
- A — Active
- FDA-listed holder
- SHANGHAI DA'AN XIN BIOMEDICAL CO LTD
Traceable filing record
FDA DMF 43871
Filing details checked against the FDA 2026 Q3 DMF list and reflect that quarterly snapshot. A DMF filing is not FDA drug approval.
Technical documentation
Define the package for your program.
- Batch Certificate of Analysis and agreed product specification
- Identity and chromatographic records within the agreed documentation package
- DMF reference and Letter of Authorization requirements
Related material formats
Daraxonrasib: from API to tablet premix.
Product inquiry
Talk to the Daraxon team.
Include intended use, quantity, destination and documentation requirements.